CoChat

Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway

Open access
Wang, Sheng-Fan, Chen, Meng-Shian, Chou, Yueh-Ching, Ueng, Yune-Fang, Yin, Pen-Hui, Yeh, Tien-Shun, Lee, Hsin-Chen · 2016 · Oncotarget
Cited by 93

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Sheng-Fan Wang 1, 2 , Meng-Shian Chen 1 , Yueh-Ching Chou 1, 2, 3 , Yune-Fang Ueng 1, 4, 5 , Pen-Hui Yin 6 , Tien-Shun Yeh 7 , Hsin-Chen Lee 1 1 Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan 2 Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan 3 School of Pharmacy, Taipei Medical University, Taipei, Taiwan 4 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan 5 Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan 6 Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan 7 Institute of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei, Taiwan Correspondence to: Hsin-Chen Lee, email: hclee2@ym.edu.tw Keywords: gastric cancer, mitochondrial dysfunction, cisplatin resistance, xCT, retrograde signaling Received: June 14, 2016 Accepted: September 21, 2016 Published: September 30, 2016 ABSTRACT Mitochondrial DNA mutations and defects in mitochondrial enzymes have been identified in gastric cancers, and they might contribute to cancer progression. In previous studies, mitochondrial dysfunction was induced by oligomycin-enhanced chemoresistance to cisplatin. Herein, we dissected the regulatory mechanism for mitochondrial dysfunction-enhanced cisplatin resistance in human gastric cancer cells. Repeated cisplatin treatment-induced cisplatin-resistant cells exhibited high SLC7A11 (xCT) expression, and xCT inhibitors (sulfasalazine or erastin), xCT siRNA, or a GSH synthesis inhibitor (buthionine sulphoximine, BSO) could sensitize these cells to cisplatin. Clinically, the high expression of xCT was associated with a poorer prognosis for gastric cancer patients under adjuvant chemotherapy. Moreover, we found that mitochondrial dysfunction enhanced cisplatin resistance and up-regulated xCT expression, as well as intracellular glutathione (GSH). The xCT inhibitors, siRNA against xCT or BSO decreased mitochondrial dysfunction-enhanced cisplatin resistance. We further demonstrated that the upregulation of the eIF2α-ATF4 pathway contributed to mitochondrial dysfunction-induced xCT expression, and activated eIF2α kinase GCN2, but not PERK, stimulated the eIF2α-ATF4-xCT pathway in response to mitochondrial dysfunction-increased reactive oxygen species (ROS) levels. In conclusion, our results suggested that the ROS-activated GCN2-eIF2α-ATF4-xCT pathway might contribute to mitochondrial dysfunction-enhanced cisplatin resistance and could be a potential target for gastric cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12356

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 93

Metadata

Authors
Wang, S.-F., Chen, M.-S., Chou, Y.-C., Ueng, Y.-F., Yin, P.-H., Yeh, T.-S., & Lee, H.-C.
Venue
Oncotarget
Published
2016-09-30
Volume
7
Issue
45
Pages
74132-74151
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2525112160
Cited by
93
References
7
FWCI
2.86
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. https://app.cochat.ai/papers/10.18632/oncotarget.12356
The paper
Wang, S.-F., Chen, M.-S., Chou, Y.-C., Ueng, Y.-F., Yin, P.-H., Yeh, T.-S., & Lee, H.-C. (2016). Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget. https://doi.org/10.18632/oncotarget.12356

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.